Should Patients Switched from D to B in the GOLD 2017 Classification be Discontinued from Inhaled Corticosteroids?

References

• Barrecheguren M, Monteagudo M, Ferrer J, Borrell E, Llor C, Esquinas C, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med 2016;111:47–53.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:347–365.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol 2017;53:128–149.
   PubMed Web of Science ®Google Scholar
• Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A, et al. GOLD 2017 on the way to phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J 2017;49:1602518.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish COPD guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease. Arch Bronconeumol 2017;53:324–335.
   PubMed Web of Science ®Google Scholar
• Koblizek V, Chlumsky J, Zindr V, Neumannova K, Zatloukal J, Zak J, et al. Chronic obstructive pulmonary disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap 2013;157:189–201.
   PubMed Web of Science ®Google Scholar
• Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto JT, Katajisto M, et al. Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines. Basic Clin Pharmacol Toxicol 2015;116:291–307.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Alvarez-Gutierrez FJ, Calle M, Casanova C, Cosio BG, López-Viña A, et al. Algorithm for identification of asthma–COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J 2017;1(49):1700068.
   Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J 2016;47:625–637.
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J 2015;45:525–537.
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;10:CD010115.
   Google Scholar
• Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66:699–708.
   PubMed Web of Science ®Google Scholar
• Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;123:1001–1006.
   PubMed Web of Science ®Google Scholar
• van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1358–1363.
   PubMed Web of Science ®Google Scholar
• Choudhury AB, Dawson CM, Kilvington HE, Eldridge S, James W-Y, Wedzicha JA, et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respir Res 2007;8:93.
   PubMed Web of Science ®Google Scholar
• Wouters EFM, Postma DS, Fokkens B, Hop WCJ, Prins J, Kuipers AF, et al. COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group t. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480–487.
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, Olmo R, del Papi A, Wehbe L, Quinn M, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J 2014;44:1548–1556.
   PubMed Web of Science ®Google Scholar
• Rossi A, Guerriero M, Corrado A, Group OS. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014;15:77.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Worth H, Buhl R, Criée CP, Lossi NS, Mailänder C, Kardos P. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis 2017 Feb 1;12:487–494.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285–1294.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. FLAME investigators. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964–971.
   PubMed Web of Science ®Google Scholar
• Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005;60:193–198.
   PubMed Web of Science ®Google Scholar
• Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis 2016;11:1495–1504.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435–442.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523–525.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4:390–398.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EFM, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; rccm.201612-2525LE.
   Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, et al. Blood eosinophils and response to maintenance COPD treatment: data from the FLAME trial. Am J Respir Crit Care Med 2017; rccm.201701-0193OC.
   Web of Science ®Google Scholar
• Santos S, Marin A, Serra-Batlles J, de la Rosa D, Solanes I, Pomares X, et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obst Pulm Dis 2016;11:515–525.
   PubMed Web of Science ®Google Scholar
• Barrecheguren M, Esquinas C, Miravitlles M. The asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challenges. Curr Opin Pulm Med 2015;21:74–79.
   PubMed Web of Science ®Google Scholar